The site will be unavailable from 11:00 PM GMT on Tuesday, 21 July 2026, until 4:00 AM GMT on Wednesday, 22 July 2026, due to scheduled maintenance.

This plain language summary from Neurodegenerative Disease Management describes the MAGNIFY-MS study, which investigated whether cladribine tablets affect how well the body responds to flu and chickenpox virus vaccines in people with multiple sclerosis.

Read the full article here.

The original article on which this plain language summary is based is titled ‘Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis’ and was published in the Multiple Sclerosis Journal. Read the original article here.